electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
6.20
-0.13 (-2.05%)
At close: Mar 13, 2026, 4:00 PM EDT
6.14
-0.06 (-0.97%)
After-hours: Mar 13, 2026, 4:04 PM EDT
electroCore Revenue
electroCore had revenue of $8.69M in the quarter ending September 30, 2025, with 32.58% growth. This brings the company's revenue in the last twelve months to $29.84M, up 27.90% year-over-year. In the year 2024, electroCore had annual revenue of $25.18M with 57.09% growth.
Revenue (ttm)
$29.84M
Revenue Growth
+27.90%
P/S Ratio
1.65
Revenue / Employee
$408,699
Employees
73
Market Cap
49.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.18M | 9.15M | 57.09% |
| Dec 31, 2023 | 16.03M | 7.44M | 86.57% |
| Dec 31, 2022 | 8.59M | 3.14M | 57.62% |
| Dec 31, 2021 | 5.45M | 1.96M | 55.93% |
| Dec 31, 2020 | 3.50M | 1.11M | 46.25% |
| Dec 31, 2019 | 2.39M | 1.40M | 140.72% |
| Dec 31, 2018 | 992.95K | 181.50K | 22.37% |
| Dec 31, 2017 | 811.46K | 557.32K | 219.30% |
| Dec 31, 2016 | 254.14K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 436.97M |
| Outset Medical | 119.48M |
| Pulmonx | 90.50M |
| Cytosorbents | 36.98M |
| Sensus Healthcare | 27.48M |
| Spectral AI | 23.17M |
| Elutia | 12.29M |
| NeuroOne Medical Technologies | 11.72M |
ECOR News
- 5 days ago - electroCore to Participate at the 38th Annual Roth Conference - GlobeNewsWire
- 6 days ago - electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026 - GlobeNewsWire
- 7 weeks ago - Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore's gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”) - GlobeNewsWire
- 7 weeks ago - electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million - GlobeNewsWire
- 2 months ago - electroCore, Inc. (ECOR) Discusses Neuromodulation Platform, Business Evolution, and Strategic Priorities Transcript - Seeking Alpha
- 3 months ago - TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen - GlobeNewsWire
- 4 months ago - electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - GlobeNewsWire
- 4 months ago - electroCore, Inc. (ECOR) Q3 2025 Earnings Call Transcript - Seeking Alpha